Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:EGLT
- CUSIP: N/A
- Web: www.egalet.com
- Market Cap: $60.27 million
- Outstanding Shares: 26,263,000
- 50 Day Moving Avg: $1.22
- 200 Day Moving Avg: $2.68
- 52 Week Range: $1.01 - $10.00
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.25
- P/E Growth: 0.00
- Annual Revenue: $22.53 million
- Price / Sales: 1.63
- Book Value: ($1.48) per share
- Price / Book: -0.95
- EBIDTA: ($79,770,000.00)
- Net Margins: -444.50%
- Return on Equity: -607.49%
- Return on Assets: -79.76%
- Debt-to-Equity Ratio: -3.22%
- Current Ratio: 3.11%
- Quick Ratio: 3.04%
- Average Volume: 612,464 shs.
- Beta: 0.29
- Short Ratio: 4.61
Frequently Asked Questions for Egalet Corporation (NASDAQ:EGLT)
What is Egalet Corporation's stock symbol?
Egalet Corporation trades on the NASDAQ under the ticker symbol "EGLT."
How were Egalet Corporation's earnings last quarter?
Egalet Corporation (NASDAQ:EGLT) announced its earnings results on Wednesday, August, 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by $0.10. The firm earned $6.26 million during the quarter, compared to analysts' expectations of $6.68 million. Egalet Corporation had a negative net margin of 444.50% and a negative return on equity of 607.49%. The firm's revenue for the quarter was up 81.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.97) EPS. View Egalet Corporation's Earnings History.
When will Egalet Corporation make its next earnings announcement?
Where is Egalet Corporation's stock going? Where will Egalet Corporation's stock price be in 2017?
5 brokers have issued 12 month target prices for Egalet Corporation's stock. Their forecasts range from $6.00 to $9.50. On average, they anticipate Egalet Corporation's share price to reach $7.10 in the next twelve months. View Analyst Ratings for Egalet Corporation.
What are analysts saying about Egalet Corporation stock?
Here are some recent quotes from research analysts about Egalet Corporation stock:
- 1. Cantor Fitzgerald analysts commented, "What’s Going On: EGLT is currently trading at ~$2/share, well below their cash/share of ~$4/share with no news and a recent positive analyst meeting." (6/1/2017)
- 2. According to Zacks Investment Research, "Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom. " (5/10/2017)
Who are some of Egalet Corporation's key competitors?
Some companies that are related to Egalet Corporation include Cidara Therapeutics (CDTX), Gemphire Therapeutics (GEMP), Galmed Pharmaceuticals (GLMD), MaxCyte (MXCT), MEI Pharma (MEIP), Otonomy (OTIC), Intec Pharma (NTEC), Affimed N.V. (AFMD), Dicerna Pharmaceuticals (DRNA), Ophthotech Corporation (OPHT), Zafgen (ZFGN), ADMA Biologics (ADMA), ProNAi Therapeutics (SRRA), Lipocine (LPCN), Aeglea BioTherapeutics (AGLE), Pfenex (PFNX), Ergomed PLC (ERGO) and ImmuPharma PLC (IMM).
Who are Egalet Corporation's key executives?
Egalet Corporation's management team includes the folowing people:
- Timothy P. Walbert, Independent Chairman of the Board
- Robert Radie, President, Chief Executive Officer, Director
- Stanley J. Musial, Chief Financial Officer, Executive Vice President, Secretary
- Mark Strobeck Ph.D., Chief Operating Officer, Executive Vice President
- Paul C. Varki J.D., Senior Vice President, General Counsel
- E. Blair Clark-Schoeb, Senior Vice President - Communications
- Karsten Lindhardt Ph.D., Senior Vice President - Research & Development
- Barbara Carlin, Chief Accounting Officer
- Jeffrey M. Dayno M.D., Chief Medical Officer
- Patrick M. Shea, Chief Commercial Officer
Who owns Egalet Corporation stock?
Egalet Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Omega Fund Management LLC (11.54%), Franklin Resources Inc. (10.92%), FMR LLC (9.30%), Federated Investors Inc. PA (4.91%), GMT Capital Corp (1.90%) and Vanguard Group Inc. (2.18%). Company insiders that own Egalet Corporation stock include Deanne F Melloy, Jeffrey M Dayno, Mark Strobeck, Patrick M Shea, Paul Varki, Robert S Radie and Stan Musial. View Institutional Ownership Trends for Egalet Corporation.
Who sold Egalet Corporation stock? Who is selling Egalet Corporation stock?
Egalet Corporation's stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., FMR LLC, Vanguard Group Inc. and Tiverton Asset Management LLC. Company insiders that have sold Egalet Corporation stock in the last year include Jeffrey M Dayno, Mark Strobeck, Patrick M Shea, Paul Varki, Robert S Radie and Stan Musial. View Insider Buying and Selling for Egalet Corporation.
Who bought Egalet Corporation stock? Who is buying Egalet Corporation stock?
Egalet Corporation's stock was bought by a variety of institutional investors in the last quarter, including GMT Capital Corp, Goldman Sachs Group Inc., LMR Partners LLP, Virtu KCG Holdings LLC, New Jersey Better Educational Savings Trust, HighTower Advisors LLC and Janney Montgomery Scott LLC. View Insider Buying and Selling for Egalet Corporation.
How do I buy Egalet Corporation stock?
Shares of Egalet Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Egalet Corporation's stock price today?
MarketBeat Community Rating for Egalet Corporation (NASDAQ EGLT)MarketBeat's community ratings are surveys of what our community members think about Egalet Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Egalet Corporation stock can currently be purchased for approximately $1.40.
Earnings History for Egalet Corporation (NASDAQ:EGLT)Earnings History by Quarter for Egalet Corporation (NASDAQ EGLT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/3/2017|| || || || || || || || |
|8/9/2017||Q2 2017||($0.94)||($1.04)||$6.68 million||$6.26 million||View||Listen|
|5/10/2017||Q1 2017||($0.90)||($1.02)||$6.92 million||$5.57 million||View||N/A|
|3/9/2017||Q4 2016||($0.92)||($0.87)||$5.37 million||$6.14 million||View||Listen|
|11/4/2016||Q316||($0.90)||($1.10)||$4.50 million||$4.70 million||View||N/A|
|8/4/2016||Q216||($0.82)||($0.97)||$3.83 million||$3.45 million||View||N/A|
|5/10/2016||Q116||($0.87)||($0.76)||$3.50 million||$2.70 million||View||Listen|
|3/8/2016||Q415||($0.91)||($0.28)||$2.80 million||$2.10 million||View||N/A|
|11/4/2015||Q315||($0.90)||($0.81)||$1.62 million||$1.30 million||View||N/A|
|8/6/2015||Q215||($1.02)||($0.98)||$0.95 million||$0.96 million||View||N/A|
|5/7/2015||Q1 2015||($0.98)||($1.02)||$3.00 million||$0.81 million||View||N/A|
|3/16/2015||Q414||($0.71)||($0.52)||$0.30 million||$0.83 million||View||N/A|
Earnings Estimates for Egalet Corporation (NASDAQ:EGLT)
Current Year EPS Consensus Estimate: $-2.79 EPS
Next Year EPS Consensus Estimate: $-1.12 EPS
Dividend History for Egalet Corporation (NASDAQ:EGLT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Egalet Corporation (NASDAQ:EGLT)
Insider Ownership Percentage: 3.80%Insider Trades by Quarter for Egalet Corporation (NASDAQ:EGLT)
Institutional Ownership Percentage: 32.61%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/3/2017||Patrick M. Shea||Insider||Sell||910||$2.35||$2,138.50|| |
|7/3/2017||Paul Varki||SVP||Sell||806||$2.35||$1,894.10|| |
|7/3/2017||Stan Musial||CFO||Sell||3,480||$2.36||$8,212.80|| |
|6/30/2017||Mark Strobeck||COO||Sell||8,700||$2.39||$20,793.00|| |
|4/3/2017||Paul Varki||SVP||Sell||806||$5.05||$4,070.30|| |
|4/3/2017||Stan Musial||CFO||Sell||8,613||$5.04||$43,409.52|| |
|3/31/2017||Jeffrey M Dayno||Insider||Sell||536||$5.16||$2,765.76|| |
|3/31/2017||Mark Strobeck||COO||Sell||8,700||$5.11||$44,457.00|| |
|3/20/2017||Patrick M Shea||Insider||Sell||4,250||$4.75||$20,187.50|| |
|1/3/2017||Jeffrey M Dayno||Insider||Sell||536||$7.75||$4,154.00|| |
|1/3/2017||Paul Varki||SVP||Sell||806||$7.75||$6,246.50|| |
|1/3/2017||Stan Musial||CFO||Sell||13,480||$7.73||$104,200.40|| |
|12/30/2016||Mark Strobeck||COO||Sell||8,700||$7.81||$67,947.00|| |
|10/3/2016||Paul Varki||SVP||Sell||806||$7.56||$6,093.36|| |
|10/3/2016||Robert S Radie||Insider||Sell||15,000||$7.47||$112,050.00|| |
|10/3/2016||Stan Musial||CFO||Sell||13,480||$7.47||$100,695.60|| |
|9/30/2016||Jeffrey M Dayno||Insider||Sell||536||$7.69||$4,121.84|| |
|9/30/2016||Mark Strobeck||COO||Sell||33,700||$7.58||$255,446.00|| |
|7/6/2016||Robert S Radie||CEO||Sell||15,000||$5.01||$75,150.00|| |
|7/5/2016||Robert S Radie||CEO||Sell||5,000||$4.94||$24,700.00|| |
|7/5/2016||Stan Musial||CFO||Sell||13,480||$5.06||$68,208.80|| |
|7/1/2016||Robert S Radie||CEO||Sell||5,000||$5.07||$25,350.00|| |
|7/1/2016||Stan Musial||CFO||Sell||10,000||$5.06||$50,600.00|| |
|6/30/2016||Jeffrey M Dayno||Insider||Sell||536||$4.65||$2,492.40|| |
|4/5/2016||Deanne F Melloy||Insider||Sell||860||$6.96||$5,985.60|| |
|4/5/2016||Robert S Radie||CEO||Sell||5,000||$6.99||$34,950.00|| |
|4/4/2016||Robert S Radie||CEO||Sell||10,000||$6.97||$69,700.00|| |
|1/11/2016||Robert S. Radie||CEO||Sell||10,000||$9.65||$96,500.00|| |
|1/6/2016||Robert S. Radie||CEO||Sell||5,000||$10.52||$52,600.00|| |
|10/6/2015||Deanne F Melloy||Insider||Sell||860||$11.42||$9,821.20|| |
|10/1/2015||Robert S Radie||CEO||Sell||15,000||$12.27||$184,050.00|| |
|10/1/2015||Stan Musial||CFO||Sell||8,480||$12.32||$104,473.60|| |
|9/30/2015||Mark Strobeck||Insider||Sell||5,220||$12.56||$65,563.20|| |
|7/8/2015||Robert S Radie||CEO||Sell||6,000||$11.97||$71,820.00|| |
|7/6/2015||Robert S Radie||CEO||Sell||9,000||$12.53||$112,770.00|| |
|7/1/2015||Mark Strobeck||Insider||Sell||10,440||$12.98||$135,511.20|| |
|7/1/2015||Stan Musial||CFO||Sell||8,480||$13.20||$111,936.00|| |
|4/1/2015||Robert S Radie||CEO||Sell||11,130||$11.25||$125,212.50|| |
|2/3/2015||Jeffrey M Dayno||Insider||Sell||2,500||$8.87||$22,175.00|| |
|1/2/2015||Mark Strobeck||Insider||Sell||3,480||$5.09||$17,713.20|| |
|1/2/2015||Robert S Radie||CEO||Sell||11,130||$5.11||$56,874.30|| |
|9/10/2014||Robert S Radie||CEO||Sell||40,040||$9.61||$384,784.40|| |
|9/8/2014||Robert S Radie||CEO||Sell||49,000||$9.74||$477,260.00|| |
|8/13/2014||Mark Strobeck||Insider||Sell||5,135||$9.20||$47,242.00|| |
|8/11/2014||Mark Strobeck||Insider||Sell||5,700||$10.28||$58,596.00|| |
|8/7/2014||Mark Strobeck||Insider||Sell||3,085||$11.50||$35,477.50|| |
|8/7/2014||Stan Musial||CFO||Sell||13,920||$11.05||$153,816.00|| |
|2/11/2014||Jean Francois Formela||Director||Buy||41,667||$12.00||$500,004.00|| |
|2/11/2014||Life Science Ventures Sunstone||Major Shareholder||Buy||133,333||$12.00||$1,599,996.00|| |
Headline Trends for Egalet Corporation (NASDAQ:EGLT)
Latest Headlines for Egalet Corporation (NASDAQ:EGLT)
Egalet Corporation (EGLT) Chart for Friday, September, 22, 2017